This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated September 2026 quarter revenue up 40%, profit after tax up 68%
RUBICON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated quarter ended September 30, 2026: revenue from operations was Rs 5,763.83 million, up 39.9% from Rs 4,120.18 million a year earlier; profit after tax rose 67.9% to Rs 904.26 million from Rs 538.52 million. Operating profit before interest, tax, depreciation and amortisation was 24.5% of revenue, up from 22.9%. Arinna was consolidated from April 30, 2026, so the year-earlier comparison is affected by the acquisition.
Reported growth may support the stock, but Arinna was added during the year, so the rise does not fully reflect existing operations.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹576.4 Cr | ₹412.0 Cr | +39.9% |
| Operating profit | ₹114.6 Cr | ₹71.01 Cr | +61.4% |
| Profit after tax | ₹90.43 Cr | ₹53.85 Cr | +67.9% |
| EBITDA margin | 25.0% | 22.9% | +2.1 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.